Acute LeukemiaNCT01728402
Pathogenesis of Hematologic Malignancies
An observational study of Acute Leukemia and Lymphoproliferative Disorders, run by OHSU Knight Cancer Institute at 1 site in United States.
Trial summary
The cause of blood and bone marrow cancers is poorly understood; however, most research focuses on how cancer cells grow and develop. Because the causes of these cancers are unknown, current treatments may be unnecessarily harsh and often do not provide a cure. Read more about this study
- Who is it for?
- Ages 1 year and older
- Conditions the study is for
- Acute Leukemia, Lymphoproliferative Disorders, Myeloproliferative Disorders
- What is being tested?
- blood draw, bone marrow procedure, or tissue biopsy
- Type of treatment
- Surgery or procedure
- How many people
- 5,000 participants
- Where
- 1 siteUnited States
- Study dates
- Sep 2008to not given
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 year and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients of any age with a diagnosis or suspected diagnosis of a blood or bone marrow cancer may be a part of this study. The provider who will perform the blood draw, bone marrow aspirate, or biopsy as part of the patient's routine care will identify possible participants from their clinic schedule or patient list, give them information about what would be involved in participating in the study including possible risks, and ask if they are interested in participating.
Who may be able to join
- Suspected or confirmed diagnosis of AL, LPD, MDS, or MPD
- Male or female of all ages
- Willing and able to sign informed consent
- Willing guardian consent for participants under 18 years of age
Who cannot join
- No suspected or confirmed diagnosis of acute leukemias (AL), lymphoproliferative disorders (LPD), myelodysplastic syndromes (MDS), or myeloproliferative diseases (MPD)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
OHSU Knight Cancer Institute
Portland, Oregon, 97239
About this study
Official title: Pathogenesis of Acute Leukemia, Lymphoproliferative Disorders, and Myeloproliferative Disorders
The cause of blood and bone marrow cancers is poorly understood; however, most research focuses on how cancer cells grow and develop. Because the causes of these cancers are unknown, current treatments may be unnecessarily harsh and often do not provide a cure. Identifying the causes of blood cancers would allow for the development of treatments that are more likely to provide a cure. To find the causes of blood and bone marrow cancers, we will look for specific cancer cell abnormalities that are responsible for cancer cell growth. We will then look to see if drugs that can reverse these abnormalities can kill cancer cells.
- Conditions
- Acute Leukemia, Lymphoproliferative Disorders, Myeloproliferative Disorders, Myelodysplastic Syndromes
- Being tested
- blood draw, bone marrow procedure, or tissue biopsy
- Medical subject headings
- Lymphoproliferative Disorders, Myeloproliferative Disorders, Myelodysplastic Syndromes
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
blood draw, bone marrow procedure, or tissue biopsyProcedure or surgery
| Study group | Role | What they receive |
|---|---|---|
| Blood Draw | Not described Receives: Procedure: blood draw, bone marrow procedure, or tissue biopsy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Identify and determine the frequency of mutations causing aberrant signaling pathway function in patients with acute leukemias (AL), lymphoproliferative disorders (LPD), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN)
Integrated functional genomics studies (whole genome sequencing, RNAi, proteomics, drug sensitivity, expression profiling) will be used to identify aberrant signaling pathways that contribute to the formation of hematologic malignancies.
Measured: After laboratory analyses are complete. Lab samples are collected at the time of a scheduled blood draw, bone marrow procedure, tissue biopsy, or other visit for usual medical care
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Nov 2012 (estimated)
- Study startSep 2008
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute LeukemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 5,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- OHSU Knight Cancer Institute
- Sponsor type
- University, hospital or other
- Collaborators
- National Institutes of Health (NIH), National Cancer Institute (NCI)
- Responsible party
- Principal investigator, Cristina Tognon, OHSU Knight Cancer Institute
- Investigators
- Cristina Tognon, PhD, Principal investigator, OHSU Knight Cancer Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01728402
- Sponsor's protocol ID
- IRB00004422
- Other IDs
- 5R21CA159265
- Status last verified
- Aug 2026
- First submitted
- 13 Nov 2012
- Last updated
- 13 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pathogenesis of Acute Leukemia, Lymphoproliferative Disorders, and Myeloproliferative Disorders
- ClinicalTrials.gov ID
- NCT01728402
- Acronym / sponsor ID
- IRB00004422
- Conditions
- Acute Leukemia, Lymphoproliferative Disorders, Myeloproliferative Disorders, Myelodysplastic Syndromes
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 5,000 participants (estimated)
- Lead sponsor
- OHSU Knight Cancer InstituteUniversity, hospital or other
- Collaborators
- National Institutes of Health (NIH), National Cancer Institute (NCI)
- Study start
- Sep 2008
- First posted
- 19 Nov 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The cause of blood and bone marrow cancers is poorly understood; however, most research focuses on how cancer cells grow and develop. Because the causes of these cancers are unknown, current treatments may be unnecessarily harsh and often do not provide a cure. Identifying the causes of blood cancers would allow for the development of treatments that are more likely to provide a cure. To find the causes of blood and bone marrow cancers, we will look for specific cancer cell abnormalities that are responsible for cancer cell growth. We will then look to see if drugs that can reverse these abnormalities can kill cancer cells.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Blood Draw | – | Procedure: blood draw, bone marrow procedure, or tissue biopsy |
Who may qualify
- Ages
- 1 year and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients of any age with a diagnosis or suspected diagnosis of a blood or bone marrow cancer may be a part of this study. The provider who will perform the blood draw, bone marrow aspirate, or biopsy as part of the patient's routine care will identify possible participants from their clinic schedule or patient list, give them information about what would be involved in participating in the study including possible risks, and ask if they are interested in participating.
Key inclusion criteria (4 listed)
- Suspected or confirmed diagnosis of AL, LPD, MDS, or MPD
- Male or female of all ages
- Willing and able to sign informed consent
- Willing guardian consent for participants under 18 years of age
Key exclusion criteria (1 listed)
- No suspected or confirmed diagnosis of acute leukemias (AL), lymphoproliferative disorders (LPD), myelodysplastic syndromes (MDS), or myeloproliferative diseases (MPD)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| blood draw, bone marrow procedure, or tissue biopsy | Procedure or surgery | Blood Draw |
Primary outcome
Identify and determine the frequency of mutations causing aberrant signaling pathway function in patients with acute leukemias (AL), lymphoproliferative disorders (LPD), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN)
Time frame: After laboratory analyses are complete. Lab samples are collected at the time of a scheduled blood draw, bone marrow procedure, tissue biopsy, or other visit for usual medical care
Integrated functional genomics studies (whole genome sequencing, RNAi, proteomics, drug sensitivity, expression profiling) will be used to identify aberrant signaling pathways that contribute to the formation of hematologic malignancies.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Aug 2026.
Related trials for Acute Leukemia
RecruitingPhase 2
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia
RecruitingPhase 2
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia
RecruitingPhase 1
Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)
B-All, Acute Lymphoblastic Leukemia
Active, not recruitingPhase 1
CART22 Alone or in Combination With huCART19 for ALL
Chemotherapy Resistant Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
RecruitingObservational study
Establishment of a Novel Flow Cytometric Diagnostic Assay to Effectively Evaluate Immune Reconstitution After Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia
Acute Lymphobkastic Leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Cristina Tognon, PhD principal investigator
OHSU Knight Cancer Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Leukemia and Lymphoproliferative Disorders, run by OHSU Knight Cancer Institute at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 13 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Identify and determine the frequency of mutations causing aberrant signaling pathway function in patients with acute leukemias (AL), lymphoproliferative disorders (LPD), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN) (time frame: After laboratory analyses are complete. Lab samples are collected at the time of a scheduled blood draw, bone marrow procedure, tissue biopsy, or other visit for usual medical care). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2026.